Oncology Today with Dr Neil Love

Featuring perspectives from Dr Gottfried E Konecny and Dr Brian M Slomovitz, including the following topics:
Introduction (0:00)
Preventing Ovarian Cancer (1:04)
Endometrial Cancer (5:27)
Ovarian Cancer (25:36)
Cervical Cancer (54:04)

CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, including the following topics:
Case: A man in his late 70s with diabetes and metastatic bladder cancer achieves radiographic response with enfortumab vedotin (EV) and pembrolizumab but develops uncontrolled hyperglycemia (0:00)
Case: A man in his early 70s with muscle-invasive bladder cancer receives adjuvant nivolumab and experiences metastatic progression after 9 cycles of therapy (6:23)
Case: A woman in her early 70s with Lynch syndrome and metastatic upper tract bladder cancer receives EV/pembrolizumab and develops myasthenia gravis (13:59)
Case: A woman in her late 40s with FGFR3 mutant metastatic bladder cancer receives erdafitinib and experiences rising serum phosphate levels (20:04)

CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, including the following topics:
Case: A man in his early 80s with bladder cancer and metastatic progression in the viscera and lymph nodes receives enfortumab vedotin (EV) with pembrolizumab — Part 1 (0:00)
Case: A man in his early 80s with metastatic bladder cancer achieves a complete response with EV/pembrolizumab therapy but develops gastrointestinal toxicity — Part 2 (5:37)
Case: A man in his early 50s with metastatic bladder cancer receives second-line EV monotherapy intermittently (15:09)
Case: A woman in her mid 60s with bladder cancer and a history of rheumatoid arthritis develops oligometastatic progression in the lung and receives EV monotherapy (21:03)
Case: A man in his mid 80s with HER2-positive (IHC 3+) metastatic bladder cancer receives trastuzumab deruxtecan and develops ground glass opacities in his lungs concerning for pneumonitis (30:43)

CME information and select publications

Featuring perspectives from Dr Aditya Bardia, Dr Kevin Kalinsky and Dr Joyce O'Shaughnessy, including the following topics:
Introduction (0:00)
Hormone Receptor-Positive Breast Cancer — Dr Kalinsky (1:18)
HER2-Positive Breast Cancer — Dr Bardia (42:46)
Triple-Negative Breast Cancer — Dr O'Shaughnessy (1:01:41)

CME information and select publications

Featuring perspectives from Dr Rachel N Grisham, including the following topics:
Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00)
Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03)
Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on trametinib and then receives avutometinib/defactinib (16:15)
Case: A woman in her mid 60s with recurrent BRAF V600E LGSOC has concerns about side effects and receives single-agent dabrafenib (19:49)

CME information and select publications